Resverlogix(OTC) RVXCF

Market Cap$26.44M

Since IPO (2012)-96%

5 Year-85%

1 Year+2%

1 Month-3%

$0.07

+0.00%

+0.00Today

Resverlogix last closing stock price
Metric	Price	Date
Last close	USD 0.07	2026-08-26

Resverlogix stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-6.64%	USD 0.08	2026-08-13
1 month	-2.58%	USD 0.07	2026-07-27
3 month	-1.92%	USD 0.07	2026-05-27
Year to date	-3.37%	USD 0.07	2025-12-31
1 year	+2.43%	USD 0.07	2025-08-26
3 year	+17.54%	USD 0.06	2023-08-25
5 year	-84.77%	USD 0.47	2021-08-26
Since inception	-95.77%	USD 1.82	2012-03-22

Resverlogix Financials at a Glance

Market Cap

$26.44M

Revenue (TTM)

$0.00

Net Income (TTM)

-$10.48M

EPS (TTM)

-$0.03

P/E Ratio

-2.26

Dividend

$0.00

Beta (Volatility)

0.50 (Low)

Dividend

$0.00

Beta (Volatility)

0.50 (Low)

Price

$0.07

Volume

500

Open

$0.07

Price

$0.07

Volume

500

Open

$0.07

Previous Close

$0.07

Daily Range

$0.07 - $0.07

52-Week Range

$0.05 - $0.10

Estimated Earnings Date

Nov 12, 2026

Dividend

$0.00

Beta (Volatility)

0.50 (Low)

Price

$0.07

Volume

500

Open

$0.07

Previous Close

$0.07

Daily Range

$0.07 - $0.07

52-Week Range

$0.05 - $0.10

Estimated Earnings Date

Nov 12, 2026

RVXCF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Resverlogix

Resverlogix Corp. is an advanced-stage biotechnology company focused on developing therapies for significant medical conditions. The primary asset, apabetalone (RVX-208), is a small molecule bromodomain and extra-terminal inhibitor currently in Phase III clinical trials, targeting serious ailments such as cardiovascular disease and diabetes.

Products and Services

Apabetalone (RVX-208) for cardiovascular and metabolic diseases
Collaboration with Eversana for COVID-19 treatment introduction
Research and development in neurodegenerative disorders

Growth Outlook

Phase III trials for apabetalone are progressing, indicating potential market entry
Collaboration with Eversana enhances commercial readiness for COVID-19 treatment
Focus on unmet medical needs positions the company for future growth

Financial Highlights

Recent quarterly net income of -$5.93 million reflects ongoing R&D investments
Trailing twelve months (TTM) revenue remains at $0, emphasizing development stage
Cash and cash equivalents increased to $79,904, indicating liquidity management

Resverlogix Corp. operates in a high-potential sector, with its innovative approach to treating serious health conditions. The ongoing clinical trials and strategic partnerships are crucial for future revenue generation. Despite current financial challenges, the focus on unmet medical needs and the potential for market entry through collaborations may attract investor interest. The company's commitment to advancing its therapies positions it as a noteworthy player in the biotechnology industry.

AI Generated • Aug 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Donald J. McCaffrey

Website

www.resverlogix.com

Headquarters

Calgary, AB T3E 6L1, CA

RVXCF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

10.92%

Return on Capital

N/A

Return on Assets

-131.48%

Earnings Yield

-44.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$26.44M

Shares Outstanding

344.29M

Volume

500

Avg. Volume

15.07K

Financials (TTM)

Gross Profit

-$385.88K

Operating Income

-$5.31M

EBITDA

-$1.80M

Operating Cash Flow

-$3.75M

Capital Expenditure

-$104.16K

Free Cash Flow

-$3.85M

Cash & ST Invst.

$79.90K

Total Debt

$77.65M

Resverlogix Performance Analysis

Resverlogix annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Resverlogix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	N/A

Resverlogix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.01	-86.3%
2023	2023-12-31	USD -0.06	336.6%
2024	2024-12-31	USD -0.03	-55.5%
2025	2025-12-31	USD -0.03	-1.4%

Resverlogix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	42.1%
Q4	2025-12-31	66.7%
Q1	2026-03-31	-927.3%
Q2	2026-06-30	-59.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$80.89K

+24.9%

Gross Margin

0.00%

N/A

Market Cap

$26.44M

N/A

Market Cap/Employee

$1.39M

N/A

Employees

N/A

Net Income

-$5.93M

-268.5%

EBITDA

-$1.36M

-16.7%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$79.90K

+565.9%

Total Debt

$77.65M

-10.6%

Accounts Receivable

$1.06M

+83.4%

Inventory

$407.51K

-20.3%

Long Term Debt

$56.53M

+0.8%

Short Term Debt

$21.12M

+14.0%

Return on Assets

-1.31%

N/A

Return on Invested Capital

14.43%

N/A

Free Cash Flow

-$925.91K

+8.1%

Operating Cash Flow

-$925.92K

-2.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MEDIFMediPharm Labs Corp.

MEDIFMediPharm Labs Corp.$0.06-1.75%

CLYYFCelyad Oncology S.A.

CLYYFCelyad Oncology S.A.$0.28+0.00%

CLCSCell Source, Inc.

CLCSCell Source, Inc.$0.65+0.00%

ZHCLFZenith Capital Corp.

ZHCLFZenith Capital Corp.$0.05+0.00%

BBIXFBonus Biogroup Ltd.

BBIXFBonus Biogroup Ltd.$0.04+0.00%

MRESInstitute of Biomedical Research Corp.

MRESInstitute of Biomedical Research Corp.$0.00+0.00%

CWBHFCharlotte's Web Holdings, Inc.

CWBHFCharlotte's Web Holdings, Inc.$0.33-2.65%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$209.66-0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.87-0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.58-0.01%

INTCIntel

INTCIntel$88.24+0.01%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.84-0.01%

SNAPSnap

SNAPSnap$5.42-0.08%

CRECre8 Enterprise

CRECre8 Enterprise$6.81+1.65%

Questions About RVXCF

What is the current price of Resverlogix?

Resverlogix is trading at $0.07 per share.

What is the 52-week range for Resverlogix?

Over the past 52 weeks, Resverlogix has traded between $0.05 and $0.10.

How much debt does Resverlogix have?

As of the most recent reporting period, Resverlogix reported total debt of $77.75M.

How much cash does Resverlogix have on hand?

Resverlogix reported $80.00K in cash and cash equivalents in its most recent financial results.

What is Resverlogix’s dividend yield?

Resverlogix does not currently have a dividend yield.

Resverlogix(OTC) RVXCF

Resverlogix Financials at a Glance

RVXCF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Resverlogix

RVXCF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Resverlogix Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RVXCF

What is the current price of Resverlogix?

What is the 52-week range for Resverlogix?

How much debt does Resverlogix have?

How much cash does Resverlogix have on hand?

What is Resverlogix’s dividend yield?

Premium Investing Services